If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-08. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
=== Role in nuclear fuel === Americium has a lower valence and lower electronegativity than plutonium, neptunium or uranium, so in most nuclear reprocessing, americium tends to fractionate with the alkaline fission products – lanthanides, strontium, caesium, barium, yttrium – rather than with lighter actinides. Americium is therefore not recycled into new nuclear fuel unless special efforts are made. In a thermal reactor, 241Am captures a neutron to become americium-242, which quickly becomes curium-242 (or, 17.3% of the time, 242Pu) via beta decay. Both 242Cm and 242Pu are much less likely to absorb a neutron, and even less likely to fission; however, 242Cm is short-lived (half-life 160 days) and almost always undergoes alpha decay to 238Pu rather than capturing another neutron. In short, most 241Am needs to absorb two neutrons before again becoming a fissile isotope, except that that becomes 242mAm (fissile) or fissions directly.
Given the increased expression of Hsp70 in cancer, it has been suggested as a biomarker for cancer prognostics, with high levels portending poor prognosis. An oncogenic mechanism illustrates how extracellular vesicles expressing HSP70 are produced by proliferative Acute Lymphoblastic Leukemia cells and can target and compromise a healthy hematopoiesis system during leukemia development.
=== Isolation and the qualification drought (1963–1974) === The 1962 FIFA World Cup proved a false dawn. At the 1963 South American Championship in Bolivia, Colombia lost five of six matches and finished last of the seven competing nations with a single point, conceding nineteen goals in the thin air of La Paz and Cochabamba. Three successive qualifying campaigns followed the same pattern of narrow competence undone by a single heavy defeat. Colombia were beaten twice by Ecuador and thrashed 7–2 by Chile in the 1966 preliminaries, recovering only to win the return 2–0 once elimination was assured. Drawn with Brazil for Mexico 1970, they took a point from six matches against the eventual world champions and Paraguay combined, losing 6–2 in Rio de Janeiro. The 1974 campaign was the cruellest of the three. Under the Yugoslav coach Toza Veselinović, Colombia went unbeaten across four matches, drawing three and winning in Montevideo 1–0 through Willington Ortiz on 5 July 1973 — a result long remembered in Colombia as a rare reverse for Uruguay at home. Colombia finished level with Uruguay on five points but were eliminated on goal difference.
Sources: en.wikipedia.org
=== Medical and diagnostic applications === Prospective parents can be tested for being genetic carriers, or their children might be tested for actually being affected by a disease. DNA samples for prenatal testing can be obtained by amniocentesis, chorionic villus sampling, or even by the analysis of rare fetal cells circulating in the mother's bloodstream. PCR analysis is also essential to preimplantation genetic diagnosis, where individual cells of a developing embryo are tested for mutations.
With an area of 22,402,200 square kilometres (8,649,500 sq mi), the Soviet Union was the world's largest country, a status that is retained by the Russian Federation. Covering a sixth of Earth's land surface, its size was comparable to that of North America. Two other successor states are also very large — Kazakhstan ranks among the top 10 countries by land area, and Ukraine is the largest country entirely in Europe. The European portion accounted for a quarter of the country's area and was the cultural and economic centre. The eastern part in Asia extended to the Pacific Ocean to the east and Afghanistan to the south, and, except some areas in Central Asia, was much less populous. It spanned over 10,000 kilometres (6,200 mi) east to west across 11 time zones, and over 7,200 kilometres (4,500 mi) north to south. It had five climate zones: tundra, taiga, steppes, desert and mountains. The USSR, like Russia, had the world's longest border, measuring over 60,000 kilometres (37,000 mi), or 1+1⁄2 circumferences of Earth. Two-thirds of it was a coastline. The country bordered Afghanistan, the People's Republic of China, Czechoslovakia, Finland, Hungary, Iran, Mongolia, North Korea, Norway, Poland, Romania, and Turkey from 1945 to 1991. The Bering Strait separated the USSR from the United States, while the La Pérouse Strait separated it from Japan. The country's highest mountain was Communism Peak (now Ismoil Somoni Peak) in Tajikistan, at 7,495 metres (24,590 ft).
The hats of the Australian Light Horse are decorated with emu feather plumes. Trademarks of early Australian companies using the emu included Webbenderfer Bros frame mouldings (1891), Mac Robertson Chocolate and Cocoa (1893), Dyason and Son Emu Brand Cordial Sauce (1894), James Allard Pottery Wares (1906), and rope manufacturers G. Kinnear and Sons Pty. Ltd. still use it on some of their products. There are around six hundred gazetted places in Australia with "emu" in their title, including mountains, lakes, hills, plains, creeks and waterholes. During the 19th and 20th centuries, many Australian companies and household products were named after the bird. In Western Australia, Emu beer has been produced since the early 20th century and the Swan Brewery continues to produce a range of beers branded as "Emu". The quarterly peer-reviewed journal of the Royal Australasian Ornithologists Union, also known as Birds Australia, is entitled Emu: Austral Ornithology. The comedian Rod Hull featured a wayward emu puppet in his act for many years and the bird returned to the small screen in the hands of his son Toby after the puppeteer's death in 1999. In 2019, American insurance company Liberty Mutual launched an advertising campaign that features LiMu Emu, a CGI-rendered emu. The animal sanctuary, Alveus Sanctuary, has an emu named Stompy. He was their first animal ambassador, after being hand raised by the Sanctuary's founder. He is known for "giving hugs" to guests at Alveus, including Ludwig, Jaiden Animations, Jack Manifold, Hasan Piker, and Valkryae.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.